Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q3

4671.TEDINET S100SUJL
Period2023-04-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥32.3bn2023-04-01 → 2023-12-31Cons.Net sales
Revenue¥46.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥35.9bn2022-04-01 → 2022-12-31Cons.Net sales
Operating income¥1.4bn2023-04-01 → 2023-12-31Cons.Operating income
Operating income¥2.5bn2022-04-01 → 2022-12-31Cons.Operating income
Ordinary income¥1.6bn2023-04-01 → 2023-12-31Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.7bn2022-04-01 → 2022-12-31Cons.Ordinary income
Profit before tax¥1.9bn2023-04-01 → 2023-12-31Cons.Income before income taxes
Profit before tax¥2.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)¥1.3bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.3bn2023-04-01 → 2023-12-31Cons.Profit loss
Net income¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Total assets¥36.9bnat 2023-12-31Cons.Assets
Total assets¥38.9bnat 2023-03-31Cons.Assets
Total assets¥38.3bnat 2022-12-31Cons.Total assets (5-year summary)
Total liabilities¥11.1bnat 2023-12-31Cons.Liabilities
Total liabilities¥12.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥25.8bnat 2023-12-31Cons.Net assets
Net assets / equity¥26.6bnat 2023-03-31Cons.Net assets
Net assets / equity¥24.7bnat 2022-12-31Cons.Net assets (5-year summary)
Cash and deposits¥10.0bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥12.6bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥115.042023-04-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥59.32023-10-01 → 2023-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥215.292022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥146.882022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥39.432022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥114.582023-04-01 → 2023-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥214.032022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥146.232022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio69.7%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio68.2%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio64.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥377m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥19.6bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥19.6bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥0
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥1.1bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥661m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-12-31¥716m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-12-31¥716m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-12-31¥71m
—segment totalrevenue2023-04-01 → 2023-12-31¥32.3bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥32.3bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥0
—segment totalsegment profit2023-04-01 → 2023-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥362m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥23.4bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥23.4bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.5bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥590m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥469m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥469m
jpcrp040300-q3r_E04982-000ICT Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥170m
—segment totalrevenue2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 363
ItemContextValueUnit
Investment securitiesPrior1YearInstant2618000000JPY
Investment securitiesCurrentQuarterInstant3433000000JPY
Other ioaPrior1YearInstant2471000000JPY
Other ioaCurrentQuarterInstant2260000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-5000000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-4000000JPY
Investments and other assetsPrior1YearInstant5085000000JPY
Investments and other assetsCurrentQuarterInstant5689000000JPY
Noncurrent assetsPrior1YearInstant16187000000JPY
Noncurrent assetsCurrentQuarterInstant17164000000JPY
AssetsPrior1YearInstant38893000000JPY
AssetsCurrentQuarterInstant36868000000JPY
Notes and accounts payable tradePrior1YearInstant4374000000JPY
Notes and accounts payable tradeCurrentQuarterInstant5155000000JPY
Short term loans payablePrior1YearInstant－JPY
Short term loans payableCurrentQuarterInstant500000000JPY
Current portion of long term loans payablePrior1YearInstant2340000000JPY
Current portion of long term loans payableCurrentQuarterInstant－JPY
Income taxes payablePrior1YearInstant181000000JPY
Income taxes payableCurrentQuarterInstant159000000JPY
Provision clPrior1YearInstant557000000JPY
Provision clCurrentQuarterInstant192000000JPY
Other clPrior1YearInstant2111000000JPY
Other clCurrentQuarterInstant2549000000JPY
Current liabilitiesPrior1YearInstant9564000000JPY
Current liabilitiesCurrentQuarterInstant8556000000JPY
Net defined benefit liabilityPrior1YearInstant1849000000JPY
Net defined benefit liabilityCurrentQuarterInstant1810000000JPY
Asset retirement obligations nclPrior1YearInstant134000000JPY
Asset retirement obligations nclCurrentQuarterInstant61000000JPY
Other nclPrior1YearInstant752000000JPY
Other nclCurrentQuarterInstant675000000JPY
Noncurrent liabilitiesPrior1YearInstant2736000000JPY
Noncurrent liabilitiesCurrentQuarterInstant2547000000JPY
LiabilitiesPrior1YearInstant12301000000JPY
LiabilitiesCurrentQuarterInstant11103000000JPY
Capital stockPrior1YearInstant3371000000JPY
Capital stockCurrentQuarterInstant3371000000JPY
Capital surplusPrior1YearInstant3670000000JPY
Capital surplusCurrentQuarterInstant3669000000JPY
Retained earningsPrior1YearInstant19025000000JPY
Retained earningsCurrentQuarterInstant19097000000JPY
Treasury stockPrior1YearInstant-94000000JPY
Treasury stockCurrentQuarterInstant-979000000JPY
Shareholders equityPrior1YearInstant25973000000JPY
Shareholders equityCurrentQuarterInstant25158000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant535000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant526000000JPY
Valuation and translation adjustmentsPrior1YearInstant535000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant526000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass